BIO Incubator Cohort 2 Early Admissions: Long COVID Labs, Quantum Biology DAO & Curetopia
We’ve been hard at work preparing for the launch of Cohort 2 of the BIO Incubator.
After the success of the first generation of BioDAOs incubated by BIO and our ongoing Genesis launch still underway, we are proud to unveil the first BioDAOs admitted into Cohort 2.
Before diving into the first accepted BioDAOs, it’s worth noting the BIO Incubator is still accepting applications forCohort 2!
- Want to build a BioDAO? Apply here - deadline to apply is November 5, 2024!
- See our “Request for BioDAOs” to learn about scientific fields we’re eager to accelerate.
The BIO Incubator Experience
The BIO Incubator is designed for biotech luminaries who understand the power of community and want to build web3-native organizations that accelerate science. You will join the incredible community that helped create BioDAOs like VitaDAO, CerebrumDAO, HairDAO, CryoDAO and more.
The program includes:
- 4 months of dedicated acceleration support from BIO and the Molecule ecosystem
- $100,000 USDC WAGMI grant
- Suite of technical frameworks and resources to get your biotech DAO set up to launch
- Shared governance rights in the BIO protocol
- + much more
Upon completion of the BIO Incubator, BioDAOs become eligible to receive further funding, token incentives and liquidity from the BIO Network.
Our program is mostly remote, with a few in-person days to collaborate at the start and end of the program. BIO provides support across branding, marketing, community building, DAO frameworks, tokenomics, web3 legal, governance, and beyond. For more details, see our docs.
You’ll be surrounded by legendary builders in Cohort 2, including the early admitted BioDAOs below.
Cohort 2 Early Admissions
Long COVID Labs
Accelerating a cure for 100M+ Long COVID patients. By incentivizing scientists, patients and supporters to collaborate and share data, Long COVID Labs is creating an open marketplace for rapid R&D and commercialization of new treatments. Our first treatment launches November 2024.
Long COVID Labs (LCL) was founded by Rohan Dixit, a serial healthcare entrepreneur and former neuroscientist at Stanford and the Harvard-MIT-MGH Martinos Center. Rohan personally suffered from Long COVID after an initially mild COVID infection in 2020. His symptoms worsened over 2.5 years, leading him to self-experiment and seemingly cure himself.
LCL’s first treatment candidate is a combination long-acting monoclonal antibody and viral replication inhibitor. LCL scientists come from labs at Stanford, Mt. Sinai, UCSF and the biotech industry, and we welcome ideas and contributions from scientists and patients anywhere. Our goal is to find the most promising treatments as a community, quickly treat patients and publish our first results, leap-frogging slower government and academic efforts with faster, more agile trials.
Long COVID is the fastest-growing chronic health condition in human history. 14% of COVID infections result in Long COVID. The virus can be found in the body and brain for more than 200 days after the initial infection, making Long COVID a seriously unmet chronic disease. It is already estimated to cost the global economy more than $1 trillion dollars each year.
LCL was formed to scale faster, cover more research surface area, tap into global scientists, and incentivize patients to share valuable data as new COVID variants continue to evolve.
Follow Long COVID Labs on X, and listen to Rohan and fellow Long COVID researchers discuss the need for accelerating research and funding in the field.
Curetopia
Ending the 10,000 rare diseases. Curetopia is uniting patient groups and populations to tackle the $1T rare disease market. They’re going direct to patients, turning them into research scientists, and making them the center of focus.
Founder Ethan Perlstein is a YC alumnus, Harvard PhD, rare disease expert, and serial entrepreneur. There are 10,000 rare diseases with an average market size of $200M. Traditional pharma and biotech VCs often require a $1B+ market size to even begin exploring a disease. This makes the current market approach incapable of going after the thousands of $200M rare disease markets. These diseases are exactly where Curetopia shines and has a competitive advantage.
Just this year, Ethan took a drug into Stage 3 clinical trial for the treatment of the rare disease PMM2-CDG by spending just $5M (a fraction of the typical $100m costs). He did this with a completely remote and distributed team. Ethan is minting this playbook into Curetopia, so that the DAO can network and scale to tackle all rare diseases.
Curetopia’s focus is specifically on the long-tail of rare diseases, which have a 2X higher rate of FDA approval. Family members of these rare disease patients are mission-driven warriors who have a high-risk tolerance and a 24/7 work ethic, doing whatever possible to help. Curetopia networks these families and leverages Ethan's biotech experience to bring cures to market in a fraction of the time, with lower upfront costs.
Each rare disease uses the same underlying framework of data pooling, patient self-reporting, and feedback monitoring. Curetopia unifies this tooling and unique know-how to accelerate treatments. Family members and global researchers are rewarded for contributing to the rare disease community, with capital being pooled by participants to cover drug development.
Quantum Biology DAO
Advancing the field of Quantum Biology, the DAO is building a quantum microscope to observe quantum phenomena happening in real-time. Quantum Biology DAO is creating an open IP collective to research and develop therapies by manipulating quantum biology.
The Quantum Biology DAO is co-founded by CSO Clarice Aiello and CEO Geoff Anders. Dr. Aiello is a world-leading scientist in the field of quantum biology, having given more than 100 talks for NIH, NSF, NASA, MIT Lincoln Labs, Los Alamos, and the European Commission. Geoff Anders is the founder of Leverage, with more than a decade of experience leading interdisciplinary teams engaging in revolutionary science. The Quantum Bio DAO was originally located at UCLA, where it raised $3M in its first three years of operation from government and private sources.
Weak magnetic fields influence biological cells and there is strong circumstantial evidence that the mechanism is quantum. By understanding the physics behind weak magnetic field effects, it will become possible to deterministically impact the entire machinery of the cell, from oxidation rates to cellular repair to cell division rates and more.
The Quantum Bio DAO is partnered with the Quantum Biology Institute, a US non-profit that is building the quantum microscopes needed to first, definitively prove that weak magnetic field effects are a result of quantum phenomena, and second, unlock an entire new industry that takes advantage of the quantum-to-biology link. The main expected applications are in health and longevity, biomanufacturing, and drug discovery, those there are applications in further domains as well.
The Quantum Bio DAO will support research in the field of quantum biology, rewarding early supporters and incentivizing people to better understand the science. It will also own a portion of the Quantum Bio Incubator, a Delaware C corp that will help shepherd the fleet of quantum biology companies that will arise as the field explodes into prominence. This will create a virtuous cycle where research leads to commercial success and commercial success will fund new research.
Apply to Cohort 2!
We are thrilled to share more details on these and other accepted BioDAOs in the coming weeks and months. Soon after C2 applications are closed on November 5th, we’ll announce the start of Cohort 2!
Eventually, BIO holders will be able to support these projects, acquire their tokens and be part of their journeys from the start.
• Now is the time to build your BioDAO - Apply Now!
• Learn more in BIO’s Telegram channel or Discord.
